Table 1.
Summary of clinical features of the childhood Burkitt Lymphoma cases, immunohistochemistry analysis, c-MYC loci, and targeted gene sequencing performed in the study.
| Case number | Clinical features |
IHC detection of protein expression |
c-MYC trans | Diagnosis | TGS analysis | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | Age | Clinical stage | Prognosis | LDH | UA | Other symptoms | MYC | ID3 | TCF3 | CCND3 | TNFAIP3 | CCND2 | c-FLIP | CD44 | ||||
| BL-01 | M | 3y | II | Benign | N | N | +++ | + | − | ++ | − | + | ++ | − | Yes | BL | √ | |
| BL-02 | M | 11y | III | Benign | N | N | +++ | ++ | + | + | ++ | + | ++ | + | No | HGBL-NOS | √ | |
| BL-03 | M | 4y | III | Poor | N | N | R & R | ++ | +++ | − | ++ | + | + | +++ | − | Yes | BL | √ |
| BL-04 | F | 3y | III | Benign | >N | N | / | / | / | / | / | / | / | / | Yes | BL | √ | |
| BL-05 | F | 10y | III | Benign | N | N | +++ | + | − | + | + | + | ++ | +/− | No | HGBL-NOS | √ | |
| BL-06 | M | 4y | III | Benign | >N | >N | +++ | ++ | − | + | + | − | ++ | − | Yes | BL | / | |
| BL-07 | M | 5y | II | Benign | N | N | ++ | + | − | + | − | + | ++ | − | Yes* | BL | √ | |
| BL-08 | F | 7y | III | Benign | >N | N | +++ | ++ | − | ++ | + | + | +++ | − | No | HGBL-NOS | / | |
| BL-09 | M | 5y | III | Benign | >N | >N | TLS | +++ | +++ | − | + | + | + | +++ | − | Yes | BL | / |
| BL-10 | F | 1y | III | Benign | >N | N | +++ | ++ | + | + | + | + | ++ | − | Yes | BL | / | |
| BL-11 | M | 4y | III | Benign | >N | >N | +++ | ++ | − | + | ++ | − | +++ | − | Yes | BL | / | |
| BL-12 | M | 6y | III | Benign | >N | N | ++ | ++ | − | + | ++ | + | ++ | − | No | HGBL-NOS | / | |
| BL-13 | M | 6y | IV | Poor | N | N | R & M | +++ | +++ | + | + | − | + | +++ | − | Yes | BL | / |
| BL-14 | M | 9y | III | Benign | N | N | +++ | + | + | + | + | + | ++ | − | Yes | BL | √ | |
| BL-15 | M | 10y | III | Poor | >N | >N | R & M | +++ | + | − | + | − | + | +++ | − | Yes | BL | √ |
| BL-16 | M | 10y | III | Benign | N | >N | ++ | ++ | − | + | + | + | ++ | − | Yes | BL | √ | |
| BL-17 | M | 6y | II | Benign | N | N | +++ | + | − | + | + | + | ++ | − | Yes | BL | √ | |
| BL-18 | M | 2y | IV | Poor | >N | >N | Death | +++ | +++ | − | +++ | ++ | + | +++ | − | Yes | BL | √ |
| BL-19 | M | 2y | III | Benign | N | >N | +++ | + | − | + | − | + | ++ | − | Yes | BL | √ | |
Abbreviations: LDH, lactate dehydrogenase; UA, uric acid; IHC, immunohistochemistry; trans, translocation; TGS, targeted gene sequencing; M, male; F, female; y, years; N, normal value; >N, higher than normal value; R & R, relapse and refractoriness; TLS, tumor lysis syndrome; R & M, relapse and metastasis; −, no expression; +, weak positive expression; ++, moderate positive expression; +++, strong positive expression; /, data not available; *, untypical break-apart; BL, Burkitt lymphoma; HGBL-NOS, high-grade B-cell lymphoma-not otherwise specified; √, analysis performed.